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Management of Tamm–Horsfall Protein for Reliable Urinary
Analytics
Xiaomeng Xu, Karina Barreiro, Luca Musante, Oliver Kretz, Hanfei Lin, Hequn Zou,*
Tobias B. Huber, and Harry Holthofer*
Purpose: Urinary extracellular vesicles (uEVs) are a novel source of
biomarkers. However, urinary Tamm–Horsfall Protein (THP; uromodulin)
interferes with all vesicle isolation attempts, precipitates with normal urinary
proteins, thus, representing an unwanted “contaminant” in urinary assays.
Thus, the aim is to develop a simple method to manage THP eﬃciently.
Experimental design: The uEVs are isolated by hydrostatic ﬁltration dialysis
(HFD) and treated with a deﬁned solution of urea to optimize release of uEVs
from sample. Presence of uEVs is conﬁrmed by transmission electron
microscopy, Western blotting, and proteomic proﬁling in MS.
Results: Using HFD with urea treatment for uEV isolation reduces sample
complexity to a great extent. The novel simpliﬁed uEV isolation protocol
allows comprehensive vesicle proteomics analysis and should be part of any
urine analytics to release all sample constituents from THP trap.
Conclusions and clinical relevance: The method brings a quick and easy
protocol for THP management during uEV isolation, providing major beneﬁts
for comprehensive sample analytics.
1. Introduction
Urinary extracellular vesicles (uEVs) are small size (30–400 nm in
diameter) phospholipid bilayered structures actively secreted by
all cell types facing the urinary space.[1] Originating either from
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the endosomal compartment or directly
from evagination of cellular plasma
membrane, diversity of extracellular
vesicles (EV) found in urine can be con-
sidered as a snapshot of physiopatholog-
ical activity upstream in the kidney and
entire body as reﬂected by EVs ﬁltered
from circulation through the kidney.[2]
Thus, uEV proﬁling represents a lucra-
tive platform for novel biomarkers to
provide dynamic molecular information
for early disease mechanisms, prediction
of outcome and response to therapy.[3]
uEVs carry a wide variety of molecules
including specialized proteins, lipids,
and (deoxy) ribonucleic acids uniquely
protected from deleterious actions of
ubiquitous proteases, ribonucleases, and
lipases present abundantly in crude
urine.[4] The precise functions of uEVs
are not fully understood. Interestingly,
they may be shuttled from upstream cell types to more distant
target cells allowing a novel way of cell-to-cell communication.[5]
Despite the exploding interest to EV biology, there are still many
elementary challenges related, e.g., to overlapping nomenclature
of EV categories and, especially, to the methods applied to iso-
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traditional uEV isolation methods have been challenging, labor-
intensive, costly, and time consuming. Furthermore, they have
not met the inherent challenges of urine: wide ionic concentra-
tion and pH range, intra- and interindividual variability, artifacts
caused by naturally occurring urinary pigments and proteins
as well as protease eﬀects all complicating their isolation and
downstream analytical processes. Particularly, Tamm–Horsfall
protein (THP; uromodulin), the most abundant and glycan-rich
glycoprotein in urine[6] can naturally entrap a large portion of
uEVs to form ﬁlamentous networks.[7] Hence, THP represents
a signiﬁcant challenge as it distorts the spectrum of uEV classes
recovered. For MS analysis, overabundant contaminant proteins
take up a signiﬁcant total mass fraction and may bind low
abundance peptides to cause serious interference.[8]
Several methods have been proposed to eliminate THP con-
tamination. These include, e.g., use of detergents such as dithio-
threitol (DTT) and 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS),[7,9,10] salt precipitation followed by
diﬀerential centrifugation,[11] and a dilution protocol using al-
kaline pH and low ionic concentration called KeepEX.[12] Al-
though thesemethods can be successful in reducing THP level in
uEV preparations, they have obvious shortcomings. DTT reduces
disulﬁde bridges, which aﬀects original protein structure. This
directly inﬂuences proteomic analysis of EVs. CHAPS reason-
ably preserve protein conformation and enzymatic activities but
its use is more time consuming than the DTT method. KeepEX
substantially increases the volume of sample thus increasing the
processing time.
In this study, we used the Hydrostatic Filtration Dialysis in
combination with various chaotropic reagents to yield an op-
timized protocol for THP denaturation, depolymerization, and
subsequent EV release and characterized the uEVs freed from
the bulk of THP.
2. Experimental Section
Majority of reagents were purchased from Sigma–Aldrich (St.
Louis, MI) unless speciﬁed otherwise in the text.
2.1. Urine Samples
First morning void urine samples were collected from healthy
laboratory staﬀ, aged 20–44 (N = 4), during three consecutive
days. First morning void urine was processed within 3 h without
adding protease inhibitors. Urine was anonymously labeled and
pooled together. The urine collection and isolation of vesicles
were done in Dublin City University. The study design and
sample collection were approved by the Research Ethics Com-
mittee of Dublin City University (DCU REC/2014/222). All the
experiments were performed in accordance with the declaration
of Helsinki. Written informed consent was obtained from all
participants.
2.2. Vesicle Puriﬁcation
uEVs were enriched by HFD according to our previous
protocol[13] with minor modiﬁcations.[14] Brieﬂy, urine samples
Statement of clinical relevance
Urinary extracellular vesicles (uEVs) are a hot research topic
to establish disease biomarkers.However, a robust, standard-
ized isolationprotocol for uEVs is stillmissing. Tamm–Horsfall
protein (THP) is themost abundant protein in normal urine
and, at the same time, is known to interferewithmost down-
streambiochemical urine analyses and, notably, uEV isolation.
For this reason,weoptimized a simple and robustmethod suit-
able for uEV isolation andapplicable to crudeurine analytics
aswell to rid urine samples of THP interference. Themethod
includes standardized treatment of samplewith urea solution
to releasemost of uEVs fromTHPmeshwork. Thismethod
meets theneedsof a clinical research laboratory and allows
quick and easy sample process before downstreamanalytics.
Management of THPcanbe easily integrated into EV isolation
process doneby anymethodandprovidesmajor beneﬁts for
comprehensive sample analytics.
were centrifuged at 2000 × g for 30 min at room temperature
(RT). Before storing at –80 °C, 50 mL of a stock solution of 1 m
sodium citrate and 5 mm sodium EDTA disodium salt was added
to 950 mL supernatant 2000 g (SN 2000). A total of 0.1 mg sil-
ver colloid and 4.5 mg sodium dichloroisocyanurate were mixed
with the sample before HFD was performed. Then 5 mL concen-
trated SN2000 was left in the membrane, 200 mL treated Milli-Q
water (0.1mg silver colloid and 4.5mg sodium dichloroisocyanu-
rate L–1) was ﬁlled to wash the membrane. Concentrated SN2000
named as HFDa was collected.
2.3. Tamm–Horsfall Denaturation
A summary of the uEV isolation and THP elimination protocol
is shown in Figure 1A and Figure S1, Supporting Information.
One milligram of HFDa was treated with 5 mL (ﬁnal volume) of
a solution made of:
a) 200 mm dithiothreitol (DTT) in 10 mm triethanolamine.[7]
b) 1% w/v 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonic (CHAPS).[10]
c) 6 m Urea in 50 mm citrate buﬀer, pH 3.5, and 10 mm
arginine;
d) 200 mm DTT in10 mm triethanolamine plus 6 m urea,
e) 1% CHAPS and 200 mm DTT in10 mm triethanolamine.
All samples weremixed in end-over-end agitation (40 revolutions
min–1) for 1 h at RT and placed again in the HFD system using a
1000 kDa molecular weight cut-oﬀ (MWCO) dialysis membrane.
Fifty milliliters of the same buﬀer followed by 200 mL of deion-
ized (DI) water was used to remove all the proteins below the
MWCO (HFDb).
2.4. Transmission Electron Microscopy, Protein assay, Gel
Electrophoresis, and Western Blotting
A full description of the methods is provided in Supporting In-
formation (see Supporting Information Methods)
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Figure 1. Workﬂow of the uEV isolation and THP elimination (A) and sample preparation for MS analysis (B).
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2.5. Tunable Resistive Pulse Sensing
Tunable Resistive Pulse Sensing (TRPS)measurements were per-
formed with qNano instrument (Izon Ltd, Christchurch, New
Zealand) according tomanufacturer’s instructions. Polyurethane
nanopore membrane NP150 (analysis range 85–300 nm) and
NP300 (analysis range 150–900 nm; Izon Ltd) were utilized,
membranes were stretched at 46 mm (NP150) and 44.5 mm
(NP300); the voltage was set at 0.46 V (NP150) and 0.34 V
(NP300),Multipressurewas set at 2, 5, and 8mBar (NP150) and at
3, 6, and 9 mBar (NP300), respectively, to determine particle con-
centration. Electrolyte solution was made of PBS and 0.05% (v/v)
Triton X100 ﬁltered with a Millipore Millex GS 0.22 µm syringe
ﬁlter (Merck Millipore). Current pulse signals were collected us-
ing Izon Control Suite 3.1.2.268 software (Izon Ltd). Blockade
counts setting in this study was ﬁxed atminimumof 1000 events.
Calibrationwasmade using standard polystyrene particles of 100,
200, and 330 nm (CPC100B; CPC200B, and CPC400B; Izon Ltd.).
uEV fractions were sonicated for 5 min and before the analysis
with the NP150 samples were ﬁltered with a Millipore Millex GS
0.45 µm syringe ﬁlter (Merck Millipore). A full description of the
method is provided in Supporting Information (see Supporting
Information Methods).
2.6. MS Analysis
One hundredmicrogram as dry pellet ofHFDaU (Figure 1B) was
resolubilized and reduced in 100 µL of 10 mm Tris (carboxyethyl)
phosphine (TCEP), 8 m urea, 0.1 mm EDTA, and 0.2 m Tris buﬀer
PH8.8 in dark for 1 h at RT, followed by alkylation with 20 mm
iodoacetamide (IAA) in dark for 2 h. Finally, 40 mm N-acetyl cys-
teine (NAC) was used to quench the excess of IAA. The sample
was then precipitated by TCA-acetone to eliminate the excess of
salts. Samples were digested by sequencing grade trypsin in pres-
ence of 1% w/v sodium deoxycholate (DOC) in 50 mm Tris-HCl
pH 7.8 in a ratio of 1 𝜇g of trypsin for 50 𝜇g of total protein,
at +37 °C overnight. After the digestion samples were acidiﬁed
with 1% v/v formic acid (FA) to precipitate DOC, the supernatant,
along with the external proteome, was cleaned up by Sep-Pak C18
cartridge (Waters Associates, Milford, Ma) according tomanufac-
turer’s instructions.
Cleaned up samples were dissolved in 0.1% v/v TFA and 2%
v/v acetonitrile (ACN) solution, directly loaded onto an RP ana-
lytical column (300 µm id × 5 mm, packed with Acclaim PepMap
RSLC C18, 5 µm, 100 Å, nanoViper). The gradient was com-
posed of an increase from 5% to 50% solvent B (0.1% FA in
80% ACN) over 65 min, and climbing to 90% in 4 min, then
holding at 90% for 6 min. All was done at a constant ﬂow rate
of 300 nL min–1. The MS analysis was performed on Q Exac-
tive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo
Fisher Scientiﬁc).
The peptides were subjected toNSI source followed byMS/MS
in Q ExactiveTM (Thermo Fisher) coupled online to the UPLC.
Intact peptides were detected in the Orbitrap at a resolution
of 70 000. Peptides were selected for MS/MS using NCE set-
ting as 27; ion fragments were detected in the Orbitrap at
a resolution of 17 500. A data-dependent procedure that al-
ternated between one MS scan followed by 20 MS/MS scans
was applied for the top 20 precursor ions above a threshold
ion count of 1E4 in the MS survey scan with 30.0 s dynamic
exclusion. The electrospray voltage applied was 2.0 kV. Auto-
matic gain control (AGC) was used to prevent overﬁlling of the
ion trap; 1E5 ions were accumulated for generation of MS/MS
spectra. For MS scans, the m/z scan range was 350 to 1800
m/z. Fixed ﬁrst mass was set as 100 m/z. Protein identiﬁcation





DTT, urea, CHAPS, and a combination of urea-DTT andCHAPS-
DTT were used to compare THP polymer denaturation and re-
lease THP complexing with uEVs and then harvested with a sec-
ond HFD step.
Figure 2 shows the partitioning of THP, the large band at
100 kDa (Figure 2A,B), TSG101 as a general vesicle marker (Fig-
ure 2C,D), and human serum albumin (HSA) as a soluble control
protein (Figure 2E,F).
Among the chaotropic reagents and their combinations tested,
only urea in acidic buﬀer, urea, and DTT at pH 7.6 were eﬀective
to remove the bulk of THP from the vesicles fraction (Figure 2A,
lanes 3a and 4a). This fraction was ﬂushed in the ﬂow-through
(Figure 2B, lanes 3b and 4b) without aﬀecting the integrity of
vesicles as indirectly evidenced by presence of TSG101 in the re-
tentate (Figure 2C, lanes 3a and 4a) but not in the ﬂow-through
(Figure 2D, lanes 3b and 4b). Notably, while both treatments suc-
cessfully removed THP, they were practically ineﬀective to strip
vesicles fromHSA as only a small fraction of HSA was recovered
in the ﬂow-through with the DTT–urea treatment. A minimum
of 6 m urea (Figure S2, Supporting Information) in acidic pH
(Figure S3, Supporting Information)was necessary to depolymer-
ize THPﬁlaments at amolecular weight smaller than theMWCO
of the dialysis membrane (1000 kDa).
3.2. Transmission Electron Microscopy
Electronmicroscopy analysis conﬁrmed the presence of a hetero-
geneous population of vesicles in respect to size andmorphology
(Figure S4, Supporting Information). This shows there is no ap-
parent change in vesicle class proportions. Notably, THP signif-
icantly entrapped uEV into its ﬁlamentous meshwork in HFDa
samples (Figure S4A, Supporting Information), but in HFDa af-
ter urea treatment (HFDa U) samples this THP protein mesh-
work was not seen (Figure S4B, Supporting Information).
3.3. TRPS for Vesicle Size Distribution
With the particle size distribution (PSD) method used for PSD
analysis, it was evident that their number and size were closely
similar for both HFDa and HFDaU (Table S1, Supporting
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Figure 2. Colloidal Coomassie staining andWestern blotting of the fraction after the chaotropic treatments. A) Retentate from the dialysis tube (a: above
the membrane molecular cut-oﬀ). B) Flow through (b: below the membrane molecular cut -oﬀ). Ten micrograms of total protein per lane was loaded. C
and D) Detection of TSG101; E and F) Detection of human serum albumin and TSG101. Lane 1, HFDa; Lane 2a and 2b, DTT; Lane 3a and 3b, urea pH
3.5; Lane 4a and 4b, urea + DTT pH7.6; Lane 5a and 5b, CHAPS; Lane 6a and 6b, CHAPS + DTT
Information) uEVs. This result directly shows the good recovery
of uEVs after urea treatment without eﬀect to any vesicle cate-
gories.
3.4. Western Blot Analysis of uEV Markers Before (HFDa) and
After (HFDaU) Urea Treatment
Analyzed by Western blotting (Figure 3), we observed that the
level of nine EV markers (six membrane proteins and three in-
ternal EV content markers) was not aﬀected by urea treatment.
This ﬁnding shows that integrity of uEVs after urea treatment
remains intact and urea is not aﬀecting stability of vesicles. In
addition, EV markers used were not ﬁltered through the dialy-
sis membrane, nor present in HFDb urea, which would occur if
they were not protected within EV. Some of the non-EV associ-
ated proteins present in the HFDa were not signiﬁcantly aﬀected
by urea treatment. Accordingly, albumin, IgA 𝛼-chain, and IgM
𝜇-chain remained intact while minor reduction in level of IgG
𝛾-chain and 𝛼-1-antitrypsin inhibitor was seen in HFDaU.
3.5. Mass Spectrometry
Protein proﬁle of uEVs recovered by the HFDaU was done by
in-solution trypsin digestion proteomic analysis.[15] Accordingly,
we found 1171 (HFDaU1), 1176 (HFDaU2), and 1021 (HFDaU3)
proteins identiﬁed by at least two peptides with 95% of
Proteomics Clin. Appl. 2019, 1900018 © 2019 The Authors. Proteomics – Clinical Application published by
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Figure 3. Western blot analysis of uEV markers (B–J) and non EV-associated proteins (K–O) before (HFDa) and after (HFDaU) urea treatment. A)
Coomassie Staining; B) CD9; C) TSG101; D) ALIX; E) 𝛽 Actin; F) dipeptidyl peptidase 4 DPP4; G) Nephrilysin NEP; H) Podocin; I) Calbindin (CALB); J)
Rab5a; K) Human serum albumin (HSA); L) IgG 𝛾 chain; M) IgA 𝛼 chain, N) IgM 𝜇 chain; O) 𝛼1 antitrypsin inhibitor.
Proteomics Clin. Appl. 2019, 1900018 © 2019 The Authors. Proteomics – Clinical Application published by
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Figure 4. Venn diagram of the protein identiﬁcation: A) Common proteins in HFDa U1, HFDa U2, and HFDa U3; B) Common and unique proteins in
HFDa U (788), vesiclepedia (10130) and urine vesiclepedia (4835).
conﬁdence, respectively, for the three replicas of same prepara-
tions. Out of 1477 non-redundant protein identiﬁcation (HFDa
U1+U2+U3), 788 proteins were common in all three datasets
(Figure 4A). Interestingly, 771 of our protein yield were found in
the Vesiclepedia repository (Figure 4B; www.microvesicles.org),
which collects all published information EV ﬁndings, while nine
proteins have not been reported in this repository before.
Gene ontology classiﬁcation (http://www.pantherdb.org/;
large-scale gene function analysis with the PANTHER classiﬁ-
cation system; Table 1A) of those 788 proteins showed that 20
of the proteins identiﬁed in HFDaU belong to the endosomal
sorting complex required for vesicle transport (ESCRT) pathway
itself.[16] This shows that our urea treatment does not appear to
damage vesicles. Altogether around 69% of all ESCRTmachinery
components were detected from HFDaU in our study, showing
that exosomes remain abundant in the uEV fraction after urea
treatment.
Tetraspanin-enriched microdomains are yet another class of
known proteins involved in the intracellular sorting machinery
to yield microvesicles and exosomes.[17] Notably, 11, eight, and
four out of the 33 human tetraspanin proteins were identiﬁed
in HFDaU1, -U2, and -U3, respectively (see Table 1B). This di-
rectly shows that urea treatment is delicate enough not to destroy
the fragile protein components of microvesicles and exosome
biogenesis.
Using the GO biological process analysis approach, we could
show that additional ten of our found HFDaU proteins are in-
volved in cytoskeletal traﬃcking of vesicles (Tables S2 and S3,
Supporting Information).
In summary our results show that urea treatment is delicate
enough and can release uEV proteins when THP contaminant is
carefully managed.
4. Discussion
Tamm–Horsfall glycoprotein is the most abundant “normal”
physiological protein found in urine, with tendency to aggregate
and form ﬁlamentous meshworks to actively bind urinary par-
ticles, apoptotic cells[18] and interact directly with uropathogenic
bacteria.[19] Accordingly, THP appears to protect against urinary
tract infections but also prevents, e.g., calcium crystal forma-
tion and kidney stones.[20] Moreover, it regulates innate immunity
by binding to immunoglobulins and cytokines[21] evidencing the
multitude of its actions in the urine. Beyond these data, the full
physiological role of THP still remains incompletely understood.
Notably, THP level in urine appears to be a valuable indicator
of functional kidney mass[22] and the respective UMOD gene is
associated with chronic kidney disease and, especially, diabetic
kidney damage[23] by mechanisms to be fully elucidated.
Here, we show how THP directly aﬀects recovery of uEV har-
vest and distorts its downstream protein analysis. Many known
artifacts in urinary analytics are caused by THP aggregation,
which harvests free proteins, reduces the number of urinary cells,
as well as distorts extracellular vesicle yield.[14] As shown in this
study, better management of THP in urine adds new proteins
to those reported in earlier uEV studies (see www.microvesicles.
org). Notably, artifacts caused by THP similarly distort analytics
directly from crude urines.
Several approaches have been used earlier to manage the
known THP eﬀects on uEVs. These have attempted to eliminate
the bulk of urinary THP. In some approaches, reagents including
dithiothreitol (DTT)[7] or deuterated water to create sucrose cush-
ion or gradient[24] have been used. Other methods to rid THP
include size exclusion chromatography[25] or serial combination
of DTT, centrifugation, centrifugal ultraﬁltration,[26] and size ex-
clusion chromatography.[27] Yet another alternative to eliminate
THP artifacts is to induce THP polymerization with diatoma-
tous earth ﬁlter.[28] Each of these approaches may have some ben-
eﬁts but in general they are ineﬃcient, tedious, time consum-
ing, and costly. According to our hypothesis the interference with
THP occurs due to aggregation. Solubilization of these aggre-
gates could also reduce contamination of uEV. For this, we tested
three chaotropic agents, DTT, CHAPS, and urea. DTT disrupts
the polymeric network presumably by reduction of disulﬁde
bonds linking monomers.[7] CHAPS is a non-denaturating zwit-
terionic detergent suited for the disruption of nonspeciﬁc protein
interactions, while also protecting conformation of protein(s).[10]
Proteomics Clin. Appl. 2019, 1900018 © 2019 The Authors. Proteomics – Clinical Application published by
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Table 1. List of proteins identiﬁed in HFDa Urea belonging to ESCRT machinery (A) and tetraspanin family (B).
A





name Protein name HFDa U database
ESCRT-0 O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase substrate 1 1
ESCRT-I Q99816 TSG101 Tumor susceptibility gene 101 protein 7 9
Q9UK41 VPS28 Vacuolar protein sorting-associated protein 28 homolog
Q9H9H4 VPS37B Vacuolar protein sorting-associated protein 37B
A5D8V6 VPS37C Vacuolar protein sorting-associated protein 37C
Q86XT2 VPS37D Vacuolar protein sorting-associated protein 37D
Q96EY5 MVB12A Multivesicular body subunit 12A
Q9H7P6 MVB12B Multivesicular body subunit 12B
ESCRT-II Q9BRG1 VPS25 Vacuolar protein-sorting-associated protein 25 2 3
Q86VN1 VPS36 Vacuolar protein-sorting-associated protein 36
ESCRT-III O43633 CHMP2A Charged multivesicular body protein 2a 6 11
Q9UQN3 CHMP2B Charged multivesicular body protein 2b
Q96FZ7 CHMP6 Charged multivesicular body protein 6
Q9H444 CHMP4B Charged multivesicular body protein 4b
Q9NZZ3 CHMP5 Charged multivesicular body protein 5
Q7LBR1 CHMP1B Charged multivesicular body protein 1b
Vps4-Vta1 P53990 IST1 IST1 homolog (hIST1) (Putative MAPK-activating protein PM28) 4 4
Q9UN37 VPS4A Vacuolar protein sorting-associated protein 4A
O75351 VPS4B Vacuolar protein sorting-associated protein 4B
Q9NP79 VTA1 Vacuolar protein sorting-associated protein VTA1 homolog
B
Protein
accession Gene name Protein name HFDa U1 HFDa U2 HFDa U3
O60637 TSPAN3 Tetraspanin-3 √ √ √
O43657 TSPAN6 Tetraspanin-6 √ √ √
P19075 TSPAN8 Tetraspanin-8 √ √ √
O00322 UPK1A Tetraspanin-21 √ √ √
O60635 TSPAN1 TSPAN1 √ √
O14817 TSPAN4 TSPAN4 √ √
P60033 CD81 TSPAN28 √ √
P08962 CD63 TSPAN30 √ √
Q86UF1 TSPAN33 TSPAN33 √
P48509 CD151 TSPAN24 √
P27701 CD82 TSPAN27 √
Urea disrupts noncovalent bonds in proteins, thus working as
protein denaturant, and it can be used to increase solubility
of proteins.[29] In addition, arginine was experimented as a co-
solvent with urea, as it is known to increase solubility and con-
tribute to protein folding.[29]
The principles behind urea eﬀects on proteins have been ac-
tively discussed for decades but still remain unknown. Urea may
exert its eﬀect directly, by binding to the protein and disrupt-
ing van der Waals interactions resulting in denaturation. Alter-
natively, urea acts as a chaotrope, altering the hydrogen-bond
structure of water thus promoting the solvation of hydrophobic
groups. Urea can also bind to the amino acid backbone to com-
pete with native interactions in the unfolding process. Why pH
3.5 is optimum for urea action can be due to ionizable groups
like tyrosine (pKa= 10.07), cysteine (pKa= 8.33), histidine (pKa=
5.97), aspartic (pKa= 3.65), and glutamic acid (pKa= 4.25), which
could lose the negative charge, respectively. In general low pH in-
cudes very low electrostatic interactions among charged groups
while the protein backbone remains positive. The pH eﬀect on
protein–glycan moieties may also play a role.
We have shown earlier that failure to manage THP prop-
erly may lead to up to 40% loss of uEVs, thus loosing
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unselectively important uEVs of diﬀerent classes.[30] Resulting
lower uEV yields may very potentially loose valuable biomark-
ers. Furthermore, most of the earlier approaches have been lim-
ited by urine volumes: if up to 40% of uEVs are lost in THP
precipitation, bigger starting volumes are needed to compen-
sate losses in harvesting. Elimination of THP typically also adds
one extra step to EVs isolation protocols. As we demonstrate
here, management of THP can be eﬃciently integrated into
EVs isolation process with Hydrostatic Filtration Dialysis with
major beneﬁts of vastly simpliﬁed and less time consuming
procedure.
Existence of valuable biologicalmaterial entrappedwithin vesi-
cles of variable sizes has been reported since late 1980s.[31] The
seminal reports of EVs found also in urine and, especially, of their
valuable contents of structural and functional proteins, lipids,
DNA, and a variety of RNA species have created a fundamen-
tally new opportunity for simpliﬁed biomarker identiﬁcation. No-
tably, EVs appear to consist qualitatively 4–10×more of potential
biomarkers compared to use of crude urine and should thus be
preferred. Furthermore, the protein and RNA diversity of uEVs
appears well protected against, e.g., free urinary ribonuclease and
protease activities.
With the recent development of a new approach called HFD
with its optimization by urea treatment many known caveats of
conventional EV isolation techniques can be avoided as shown
here. HFD is simple, inexpensive, and easy to adopt in any labo-
ratory without costly machinery or ultracentrifugation device. It
also easily handles big volumes of urine rapidly, by itself equals
urinary electrolytes and can easily bypass known artifacts caused
by urinary pigments.
In summary, we provide here an easy method optimized to
manage challenges with urinary THP caused artifacts in all uri-
nary analytics.
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